Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.2024-0945.C1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies.
J Am Acad Dermatol
July 2025
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory
Background: Idiopathic inflammatory myopathies (IIMs) are heterogeneous autoimmune diseases with variable long-term outcomes.
Objective: To determine the prognosis of IIM.
Methods: This multicenter, prospective cohort study included Chinese patients with IIM.
Clinical impact of pneumomediastinum in patients with myositis-associated interstitial lung disease.
PLoS One
July 2025
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Background: Idiopathic inflammatory myositis (IIM) frequently coexists with interstitial lung disease (ILD), significantly impacting morbidity and mortality. Spontaneous pneumomediastinum, a complication of myositis-associated ILD, remains understudied regarding its clinical implications.
Method: We retrospectively reviewed patients diagnosed with myositis-associated ILD at Asan Medical Center, Seoul, South Korea, from April 2012 to September 2023.
Long-term clinical prognosis of anti-aminoacyl-tRNA synthetase antibodies and interstitial lung disease.
Clin Rheumatol
August 2025
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Introduction: Anti-aminoacyl tRNA synthetase (anti-ARS) antibody is the most common myositis-specific antibody subtype. Anti-ARS antibody-positive myositis is often complicated by interstitial lung disease (ILD), but the clinical progression of anti-ARS antibody-positive ILD (ARS-ILD) remains unclear.
Method: A prospectively collected, single center longitudinal myositis database was used to retrospectively investigate 131 patients with ARS-ILD based on subtypes of anti-ARS antibodies (Jo-1, PL-7, PL-12, EJ, OJ, and KS).
Association of Cancer and Anti-Synthetase Syndrome: A Retrospective Multicenter Study.
Am J Med
June 2025
Internal Medicine and Clinical Immunology Department, Nancy University Hospital, Vandoeuvre-lès-Nancy, France; UMR 7365 CNRS-Université de Lorraine IMoPA, University of Lorraine, Vandoeuvre-lès-Nancy, France. Electronic address:
Objectives: We aimed to assess the incidence of cancer-associated myositis among patients with anti-synthetase syndrome, identify factors associated with cancer-associated myositis, and assess its impact on prognosis.
Methods: We conducted a retrospective multicenter study, including adult patients with anti-synthetase syndrome. Factors associated with cancer were assessed using a multivariable logistic regression model.
Long-term outcomes of idiopathic inflammatory myopathies: a large-scale longitudinal cohort study.
J Autoimmun
June 2025
Department of Rheumatology, Key Myositis Laboratories, China-Japan Friendship Hospital, Beijing, China; China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address:
Objectives: To investigate mortality, patient-reported outcomes (PROs), and drug-free remission (DFR) in a large well-characterised cohort of idiopathic inflammatory myopathies (IIMs).
Methods: This study retrospectively enrolled 1854 patients with IIMs. Follow-up lasted up to 20 years.